Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study

Nao Souma; Tamara Isakova; David Lipiszko; Ralph L Sacco; Mitchell S V Elkind; Janet T DeRosa; Shonni J Silverberg; Armando J Mendez; Chuanhui Dong; Clinton B Wright; Myles Wolf

doi:10.1210/jc.2016-2215

Back

Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study

Journal article

Open access

Peer reviewed

Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study

Nao Souma, Tamara Isakova, David Lipiszko, Ralph L Sacco, Mitchell S V Elkind, Janet T DeRosa, Shonni J Silverberg, Armando J Mendez, Chuanhui Dong, Clinton B Wright, …

The journal of clinical endocrinology and metabolism, Vol.101(10), pp.3779-3786

2016-10

DOI: https://doi.org/10.1210/jc.2016-2215

PMCID: PMC5052338

PMID: 27501282

Abstract

Urban Population - statistics & numerical data

Follow-Up Studies

African Continental Ancestry Group - ethnology

Humans

Middle Aged

Risk Factors

Neoplasms - mortality

Hispanic Americans - statistics & numerical data

Male

Vascular Diseases - ethnology

European Continental Ancestry Group - ethnology

Cause of Death

Vascular Diseases - mortality

Neoplasms - blood

Neoplasms - ethnology

New York City - ethnology

Fibroblast Growth Factors - blood

Aged, 80 and over

Adult

Female

Aged

Vascular Diseases - blood

An elevated fibroblast growth factor (FGF) 23 is an independent risk factor for cardiovascular disease and mortality in patients with kidney disease. The relationship between FGF23 and cause-specific mortality in the general population is unknown. To investigate the association of elevated FGF23 with the risk of cause-specific mortality in a racially and ethnically diverse urban general population. The Northern Manhattan Study is a population-based prospective cohort study. Residents who were > 39 years old and had no history of stroke were enrolled between 1993 and 2001. Participants with available blood samples for baseline FGF23 testing were included in the current study (n = 2525). Cause-specific death events. A total of 1198 deaths (474 vascular, 612 nonvascular, 112 unknown cause) occurred during a median follow-up of 14 years. Compared to participants in the lowest FGF23 quintile, those in the highest quintile had a 2.07-fold higher risk (95% confidence interval [CI], 1.45, 2.94) of vascular death and a 1.64-fold higher risk (95% CI, 1.22, 2.20) of nonvascular death in fully adjusted models. Higher FGF23 was independently associated with increased risk of mortality due to cancer, but only in Hispanic participants (hazard ratio per 1 unit increase in ln FGF23 of 1.87; 95% CI, 1.40, 2.50; P for interaction = .01). Elevated FGF23 was independently associated with increased risk of vascular and nonvascular mortality in a diverse general population and with increased risk of cancer death specifically in Hispanic individuals.

Files and links (1)

url

https://doi.org/10.1210/jc.2016-2215View

Published (Version of record) Open

Metrics

24 Record Views

63 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.80 Bone Diseases; 1.80.348 Primary Hyperparathyroidism
Web Of Science research areas: Endocrinology & Metabolism
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Fibroblast Growth Factor 23 and Cause-Specific Mortality in the General Population: The Northern Manhattan Study
Creators: Nao Souma - Division of Nephrology and Hypertension, Department of Medicine, and Center for Translational Metabolism and Health, Institute for Public Health and Medicine (N.S., T.I., D.L., M.W.), Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611; Evelyn F. McKnight Brain Institute (R.L.S., C.D., C.B.W.) and Departments of Neurology (R.L.S., C.B.W.), Public Health Sciences (R.L.S., C.B.W.), Human Genomics (R.L.S.), Medicine (A.J.M.), and the Neuroscience Program (R.L.S., C.B.W.), Leonard M. Miller School of Medicine, University of Miami, Miami, Florida 33136; and Departments of Neurology (M.S.V.E., J.T.D.) and Medicine (S.J.S.), College of Physicians and Surgeons, and Department of Epidemiology (M.S.V.E.), Mailman School of Public Health, Columbia University, New York, New York 10032
Tamara Isakova - Division of Nephrology and Hypertension, Department of Medicine, and Center for Translational Metabolism and Health, Institute for Public Health and Medicine (N.S., T.I., D.L., M.W.), Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611; Evelyn F. McKnight Brain Institute (R.L.S., C.D., C.B.W.) and Departments of Neurology (R.L.S., C.B.W.), Public Health Sciences (R.L.S., C.B.W.), Human Genomics (R.L.S.), Medicine (A.J.M.), and the Neuroscience Program (R.L.S., C.B.W.), Leonard M. Miller School of Medicine, University of Miami, Miami, Florida 33136; and Departments of Neurology (M.S.V.E., J.T.D.) and Medicine (S.J.S.), College of Physicians and Surgeons, and Department of Epidemiology (M.S.V.E.), Mailman School of Public Health, Columbia University, New York, New York 10032
David Lipiszko - Division of Nephrology and Hypertension, Department of Medicine, and Center for Translational Metabolism and Health, Institute for Public Health and Medicine (N.S., T.I., D.L., M.W.), Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611; Evelyn F. McKnight Brain Institute (R.L.S., C.D., C.B.W.) and Departments of Neurology (R.L.S., C.B.W.), Public Health Sciences (R.L.S., C.B.W.), Human Genomics (R.L.S.), Medicine (A.J.M.), and the Neuroscience Program (R.L.S., C.B.W.), Leonard M. Miller School of Medicine, University of Miami, Miami, Florida 33136; and Departments of Neurology (M.S.V.E., J.T.D.) and Medicine (S.J.S.), College of Physicians and Surgeons, and Department of Epidemiology (M.S.V.E.), Mailman School of Public Health, Columbia University, New York, New York 10032
Ralph L Sacco - Division of Nephrology and Hypertension, Department of Medicine, and Center for Translational Metabolism and Health, Institute for Public Health and Medicine (N.S., T.I., D.L., M.W.), Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611; Evelyn F. McKnight Brain Institute (R.L.S., C.D., C.B.W.) and Departments of Neurology (R.L.S., C.B.W.), Public Health Sciences (R.L.S., C.B.W.), Human Genomics (R.L.S.), Medicine (A.J.M.), and the Neuroscience Program (R.L.S., C.B.W.), Leonard M. Miller School of Medicine, University of Miami, Miami, Florida 33136; and Departments of Neurology (M.S.V.E., J.T.D.) and Medicine (S.J.S.), College of Physicians and Surgeons, and Department of Epidemiology (M.S.V.E.), Mailman School of Public Health, Columbia University, New York, New York 10032
Mitchell S V Elkind - Division of Nephrology and Hypertension, Department of Medicine, and Center for Translational Metabolism and Health, Institute for Public Health and Medicine (N.S., T.I., D.L., M.W.), Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611; Evelyn F. McKnight Brain Institute (R.L.S., C.D., C.B.W.) and Departments of Neurology (R.L.S., C.B.W.), Public Health Sciences (R.L.S., C.B.W.), Human Genomics (R.L.S.), Medicine (A.J.M.), and the Neuroscience Program (R.L.S., C.B.W.), Leonard M. Miller School of Medicine, University of Miami, Miami, Florida 33136; and Departments of Neurology (M.S.V.E., J.T.D.) and Medicine (S.J.S.), College of Physicians and Surgeons, and Department of Epidemiology (M.S.V.E.), Mailman School of Public Health, Columbia University, New York, New York 10032
Janet T DeRosa - Division of Nephrology and Hypertension, Department of Medicine, and Center for Translational Metabolism and Health, Institute for Public Health and Medicine (N.S., T.I., D.L., M.W.), Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611; Evelyn F. McKnight Brain Institute (R.L.S., C.D., C.B.W.) and Departments of Neurology (R.L.S., C.B.W.), Public Health Sciences (R.L.S., C.B.W.), Human Genomics (R.L.S.), Medicine (A.J.M.), and the Neuroscience Program (R.L.S., C.B.W.), Leonard M. Miller School of Medicine, University of Miami, Miami, Florida 33136; and Departments of Neurology (M.S.V.E., J.T.D.) and Medicine (S.J.S.), College of Physicians and Surgeons, and Department of Epidemiology (M.S.V.E.), Mailman School of Public Health, Columbia University, New York, New York 10032
Shonni J Silverberg - Division of Nephrology and Hypertension, Department of Medicine, and Center for Translational Metabolism and Health, Institute for Public Health and Medicine (N.S., T.I., D.L., M.W.), Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611; Evelyn F. McKnight Brain Institute (R.L.S., C.D., C.B.W.) and Departments of Neurology (R.L.S., C.B.W.), Public Health Sciences (R.L.S., C.B.W.), Human Genomics (R.L.S.), Medicine (A.J.M.), and the Neuroscience Program (R.L.S., C.B.W.), Leonard M. Miller School of Medicine, University of Miami, Miami, Florida 33136; and Departments of Neurology (M.S.V.E., J.T.D.) and Medicine (S.J.S.), College of Physicians and Surgeons, and Department of Epidemiology (M.S.V.E.), Mailman School of Public Health, Columbia University, New York, New York 10032
Armando J Mendez - Division of Nephrology and Hypertension, Department of Medicine, and Center for Translational Metabolism and Health, Institute for Public Health and Medicine (N.S., T.I., D.L., M.W.), Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611; Evelyn F. McKnight Brain Institute (R.L.S., C.D., C.B.W.) and Departments of Neurology (R.L.S., C.B.W.), Public Health Sciences (R.L.S., C.B.W.), Human Genomics (R.L.S.), Medicine (A.J.M.), and the Neuroscience Program (R.L.S., C.B.W.), Leonard M. Miller School of Medicine, University of Miami, Miami, Florida 33136; and Departments of Neurology (M.S.V.E., J.T.D.) and Medicine (S.J.S.), College of Physicians and Surgeons, and Department of Epidemiology (M.S.V.E.), Mailman School of Public Health, Columbia University, New York, New York 10032
Chuanhui Dong - Division of Nephrology and Hypertension, Department of Medicine, and Center for Translational Metabolism and Health, Institute for Public Health and Medicine (N.S., T.I., D.L., M.W.), Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611; Evelyn F. McKnight Brain Institute (R.L.S., C.D., C.B.W.) and Departments of Neurology (R.L.S., C.B.W.), Public Health Sciences (R.L.S., C.B.W.), Human Genomics (R.L.S.), Medicine (A.J.M.), and the Neuroscience Program (R.L.S., C.B.W.), Leonard M. Miller School of Medicine, University of Miami, Miami, Florida 33136; and Departments of Neurology (M.S.V.E., J.T.D.) and Medicine (S.J.S.), College of Physicians and Surgeons, and Department of Epidemiology (M.S.V.E.), Mailman School of Public Health, Columbia University, New York, New York 10032
Clinton B Wright - Division of Nephrology and Hypertension, Department of Medicine, and Center for Translational Metabolism and Health, Institute for Public Health and Medicine (N.S., T.I., D.L., M.W.), Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611; Evelyn F. McKnight Brain Institute (R.L.S., C.D., C.B.W.) and Departments of Neurology (R.L.S., C.B.W.), Public Health Sciences (R.L.S., C.B.W.), Human Genomics (R.L.S.), Medicine (A.J.M.), and the Neuroscience Program (R.L.S., C.B.W.), Leonard M. Miller School of Medicine, University of Miami, Miami, Florida 33136; and Departments of Neurology (M.S.V.E., J.T.D.) and Medicine (S.J.S.), College of Physicians and Surgeons, and Department of Epidemiology (M.S.V.E.), Mailman School of Public Health, Columbia University, New York, New York 10032
Myles Wolf - Division of Nephrology and Hypertension, Department of Medicine, and Center for Translational Metabolism and Health, Institute for Public Health and Medicine (N.S., T.I., D.L., M.W.), Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611; Evelyn F. McKnight Brain Institute (R.L.S., C.D., C.B.W.) and Departments of Neurology (R.L.S., C.B.W.), Public Health Sciences (R.L.S., C.B.W.), Human Genomics (R.L.S.), Medicine (A.J.M.), and the Neuroscience Program (R.L.S., C.B.W.), Leonard M. Miller School of Medicine, University of Miami, Miami, Florida 33136; and Departments of Neurology (M.S.V.E., J.T.D.) and Medicine (S.J.S.), College of Physicians and Surgeons, and Department of Epidemiology (M.S.V.E.), Mailman School of Public Health, Columbia University, New York, New York 10032
Publication Details: The journal of clinical endocrinology and metabolism, Vol.101(10), pp.3779-3786
Publisher: United States
Grant note: R01 DK076116 / NIDDK NIH HHS R01 HL108623 / NHLBI NIH HHS U01 DK099930 / NIDDK NIH HHS R01 DK102438 / NIDDK NIH HHS K24 DK093723 / NIDDK NIH HHS R01 NS029993 / NINDS NIH HHS
Academic Unit: Leadership Department; Miller School of Medicine; Diabetes Research Institute (DRI); UMMG Department of Neurology
Language: English
Resource Type: Journal article
PMID: 27501282
PMCID: PMC5052338
Record Identifier: 991031560599502976